The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys

Journal of Neuroscience

Volumn 25, Issue 23, 2005, Pages 5645-5650

  Justinova, Zuzana ^a   Solinas, Marcello ^a,b   Tanda, Gianluigi ^a   Redhi, Godfrey H ^a   Goldberg, Steven R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

Anandamide; Cannabinoids; Methanandamide; Reinforcing effects; Self administration; Squirrel monkey

Indexed keywords

ANANDAMIDE; CANNABINOID DERIVATIVE; METHANANDAMIDE; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DRUG ABUSE; DRUG INHIBITION; DRUG SELF ADMINISTRATION; INTRAVENOUS DRUG ABUSE; MALE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; SIGNAL TRANSDUCTION; SQUIRREL MONKEY;

ANIMALS; ARACHIDONIC ACIDS; COCAINE; ENDOCANNABINOIDS; INFUSIONS, INTRAVENOUS; MALE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT (PSYCHOLOGY); SAIMIRI; SELF ADMINISTRATION; STEREOISOMERISM; SUBSTANCE-RELATED DISORDERS;

EID: 20444391292     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0951-05.2005     Document Type: Article

References (38)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893.
2. Aceto MD, Scates SM, Razdan RK, Martin BR (1998) Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther 287:598-605.
3. Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
4. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163.
5. Costa B, Vailati S, Colleoni M (1999) SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 10:327-331.
6. Costa B, Giagnoni G, Colleoni M (2000) Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology (Berl) 149:121-128.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
8. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernandez-Ruiz JJ (2000a) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627-1635.
9. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR (2000b) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75:2434-2444.
10. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002) Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66:377-391.
11. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784.
12. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066.
13. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363.
14. Goldberg SR (1973) Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey. J Pharmacol Exp Ther 186:18-30.
15. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81.
16. Hajos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4.
17. Jarbe TU, Lamb RJ, Lin S, Makriyannis A (2001) (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) 156:369-380.
18. Justinova Z, Tanda G, Redhi GH, Goldberg SR (2003) Self-administration of Delta(9)-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 169:135-140.
19. Ko MC, Terner J, Hursh S, Woods JH, Winger G (2002) Relative reinforcing effects of three opioids with different durations of action. J Pharmacol Exp Ther 301:698-704.
20. Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24:97-129.
21. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
22. Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22:3326-3331.
23. Mallet PE, Beninger RJ (1998) Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci 62:2431-2439.
24. Pertwee RG (2004) Novel pharmacological targets for cannabinoids. Curr Neuropharmacol 2:9-29.
25. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884.
26. Piomelli D (2004) The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology 47 [Suppl 1]:359-367.
27. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
28. Romero J, Garcia-Palomero E, Lin SY, Ramos JA, Makriyannis A, Fernandez-Ruiz JJ (1996) Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sci 58:1249-1257.
29. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R (2004) Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 176:223-232.
30. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227.
31. Solinas M, Goldberg SR (2005) Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology, in press.
32. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93-102.
33. Tanda G, Goldberg SR (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology (Berl) 169:115-134.
34. Tanda G, Munzar P, Goldberg SR (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3:1073-1074.
35. van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133-150.
36. Wiley JL, LaVecchia KL, Karp NE, Kulasegram S, Mahadevan A, Razdan RK, Martin BR (2004) A comparison of the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clin Psychopharmacol 12:173-179.
37. Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494.
38. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457.